Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6764530 | 0.85 | NAMPT (0.54) | TRPV1NAMPT | |
| SCHEMBL6764613 | 0.80 | TRPV1 (0.79) | TRPV1 | |
| SCHEMBL6832530 | 0.77 | TRPV1 (0.58) | TRPV1NAMPT | |
| SCHEMBL29865257 | 0.77 | CYP11B2 (0.42) | NAMPT | |
| SCHEMBL6764630 | 0.75 | TRPV1 (0.80) | TRPV1 | |
| SCHEMBL10308203 | 0.74 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL10308135 | 0.72 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL14020967 | 0.72 | TRPV1 (0.80) | TRPV1 | |
| SCHEMBL17655305 | 0.72 | TRPV1 (0.73) | TRPV1 | |
| SCHEMBL10308183 | 0.71 | TRPV1 (1.00) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178560-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178560-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20100331369-A1 | Therapeutic Agents Useful for Treating Pain | PURDUE PHARMA L.P. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331369-A1 | Therapeutic Agents Useful for Treating Pain | PURDUE PHARMA L.P. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331369-A1 | Therapeutic Agents Useful for Treating Pain | GRIN1, GRIK1, GRIN2B | TRPV1 135/4885NAMPT 4709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.